Eva M Grasa
Eva M Grasa
Bestätigte E-Mail-Adresse bei santpau.cat
Titel
Zitiert von
Zitiert von
Jahr
Increased frontal and paralimbic activation following ayahuasca, the pan-Amazonian inebriant
J Riba, S Romero, E Grasa, E Mena, I Carrió, MJ Barbanoj
Psychopharmacology 186 (1), 93-98, 2006
2532006
Pharmacology of ayahuasca administered in two repeated doses
RG Dos Santos, E Grasa, M Valle, MR Ballester, JC Bouso, JF Nomdedéu, ...
Psychopharmacology 219 (4), 1039-1053, 2012
1102012
Resting-state functional connectivity alterations in the default network of schizophrenia patients with persistent auditory verbal hallucinations
A Alonso-Solís, Y Vives-Gilabert, E Grasa, MJ Portella, M Rabella, ...
Schizophrenia research 161 (2-3), 261-268, 2015
962015
Premorbid adjustment and clinical correlates of cognitive impairment in first-episode psychosis. The PEPsCog Study
MJ Cuesta, AM Sánchez-Torres, B Cabrera, M Bioque, ...
Schizophrenia Research 164 (1-3), 65-73, 2015
932015
Effects of olanzapine, risperidone and haloperidol on sleep after a single oral morning dose in healthy volunteers
S Giménez, S Clos, S Romero, E Grasa, A Morte, MJ Barbanoj
Psychopharmacology 190 (4), 507-516, 2007
902007
Daytime Ayahuasca administration modulates REM and slow-wave sleep in healthy volunteers
MJ Barbanoj, J Riba, S Clos, S Giménez, E Grasa, S Romero
Psychopharmacology 196 (2), 315-326, 2008
672008
Randomized control trial to assess the efficacy of metacognitive training compared with a psycho-educational group in people with a recent-onset psychosis
S Ochoa, R López-Carrilero, ML Barrigón, E Pousa, A Barajas, ...
Psychological Medicine 47 (9), 1573-1584, 2017
582017
Mobile phone and wearable sensor-based mHealth approaches for psychiatric disorders and symptoms: systematic review
J Seppälä, I De Vita, T Jämsä, J Miettunen, M Isohanni, K Rubinstein, ...
JMIR mental health 6 (2), e9819, 2019
522019
Pharmacogenetic study of antipsychotic induced acute extrapyramidal symptoms in a first episode psychosis cohort: role of dopamine, serotonin and glutamate candidate genes
S Mas, P Gassó, A Lafuente, M Bioque, A Lobo, A Gonzàlez-Pinto, ...
The pharmacogenomics journal 16 (5), 439-445, 2016
342016
Altered amplitude of low frequency fluctuations in schizophrenia patients with persistent auditory verbal hallucinations
A Alonso-Solís, Y Vives-Gilabert, MJ Portella, M Rabella, EM Grasa, ...
Schizophrenia research 189, 97-103, 2017
292017
Neuropsychological functioning and jumping to conclusions in recent onset psychosis patients
LE González, R López-Carrilero, ML Barrigón, E Grasa, A Barajas, ...
Schizophrenia Research 195, 366-371, 2018
252018
Volumetric and morphological characteristics of the hippocampus are associated with progression to schizophrenia in patients with first-episode psychosis
R Sauras, A Keymer, A Alonso-Solis, A Díaz, C Molins, F Nuñez, ...
European Psychiatry 45, 1-5, 2017
242017
Density of striatal D2 receptors in untreated first-episode psychosis: an I123-IBZM SPECT study
I Corripio, MJ Escartí, MJ Portella, V Pérez, E Grasa, RB Sauras, A Alonso, ...
European Neuropsychopharmacology 21 (12), 861-866, 2011
232011
Influence of social cognition as a mediator between cognitive reserve and psychosocial functioning in patients with first episode psychosis
I González-Ortega, A González-Pinto, S Alberich, E Echeburúa, ...
Psychological medicine 50 (16), 2702-2710, 2020
192020
Neurophysiological evidence of impaired self-monitoring in schizotypal personality disorder and its reversal by dopaminergic antagonism
M Rabella, E Grasa, I Corripio, S Romero, MÀ Mañanas, RM Antonijoan, ...
NeuroImage: Clinical 11, 770-779, 2016
182016
Measuring users’ receptivity toward an integral intervention model based on mHealth solutions for patients with treatment-resistant schizophrenia (m-RESIST): A qualitative study
E Huerta-Ramos, MS Escobar-Villegas, K Rubinstein, ZS Unoka, E Grasa, ...
JMIR mHealth and uHealth 4 (3), e5716, 2016
172016
Cannabis use and striatal D2 receptor density in untreated first-episode psychosis: an in vivo SPECT study
G Safont, I Corripio, MJ Escartí, MJ Portella, V Pérez, M Ferrer, ...
Schizophrenia research 129 (2-3), 169-171, 2011
162011
Double-blind, placebo-controlled study of the efficacy of reboxetine and citalopram as adjuncts to atypical antipsychotics for negative symptoms of schizophrenia
J Usall, R López-Carrilero, R Iniesta, M Roca, M Caballero, ...
The Journal of clinical psychiatry 75 (6), 4768, 2014
152014
Gray and white matter changes and their relation to illness trajectory in first episode psychosis
A Keymer-Gausset, A Alonso-Solís, I Corripio, RB Sauras-Quetcuti, ...
European Neuropsychopharmacology 28 (3), 392-400, 2018
142018
Sex differences in sleep after a single oral morning dose of olanzapine in healthy volunteers
S Giménez, S Romero, I Gich, S Clos, E Grasa, A Rosa‐María, ...
Human Psychopharmacology: Clinical and Experimental 26 (7), 498-507, 2011
142011
Das System kann den Vorgang jetzt nicht ausführen. Versuchen Sie es später erneut.
Artikel 1–20